Advancing the management of double hit lymphoma

par Landsburg, Daniel J.
Publié dans Oncotarget (2017)

Molecular Risk Stratification in Aggressive B-Cell Lymphomas

par Frosch, Zachary A.K., Landsburg, Daniel J.
Publié dans J Clin Oncol (2020)

Real World Outcomes in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies

par Ayers, Emily C., Margolis, David, Landsburg, Daniel J.
Publié dans Clin Lymphoma Myeloma Leuk (2020)

Structure-Based Analysis of the Herpes Simplex Virus Glycoprotein D Binding Site Present on Herpesvirus Entry Mediator HveA (HVEM)

par Connolly, Sarah A., Landsburg, Daniel J., Carfi, Andrea, Wiley, Don C., Eisenberg, Roselyn J., Cohen, Gary H.
Publié 2002

Structure-Based Mutagenesis of Herpes Simplex Virus Glycoprotein D Defines Three Critical Regions at the gD-HveA/HVEM Binding Interface

par Connolly, Sarah A., Landsburg, Daniel J., Carfi, Andrea, Wiley, Don C., Cohen, Gary H., Eisenberg, Roselyn J.
Publié 2003

Intraventricular Brain Injection of Adeno-Associated Virus Type 1 (AAV1) in Neonatal Mice Results in Complementary Patterns of Neuronal Transduction to AAV2 and Total Long-Term Cor...

par Passini, Marco A., Watson, Deborah J., Vite, Charles H., Landsburg, Daniel J., Feigenbaum, Alyson L., Wolfe, John H.
Publié 2003

Adult nodular lymphocyte‐predominant Hodgkin lymphoma: treatment modality utilization and survival

par Alonso, Clayton, Dutta, Sunil W., Mitra, Nandita, Landsburg, Daniel J., Zaorsky, Nicholas G., Grover, Surbhi, Peterson, Jennifer, Trifiletti, Daniel M.
Publié dans Cancer Med (2018)

Potential Nectin-1 Binding Site on Herpes Simplex Virus Glycoprotein D

par Connolly, Sarah A., Landsburg, Daniel J., Carfi, Andrea, Whitbeck, J. Charles, Zuo, Yi, Wiley, Don C., Cohen, Gary H., Eisenberg, Roselyn J.
Publié 2005

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS

par Nagle, Sarah J, Shah, Nirav N, Ganetsky, Alex, Landsburg, Daniel J, Nasta, Sunita D, Mato, Anthony, Schuster, Stephen J, Reshef, Ran, Tsai, Donald E, Svoboda, Jakub
Publié dans Int J Hematol Oncol (2017)

Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia

par Linaburg, Taylor, Davis, Adam R., Frey, Noelle V., Khawaja, Muhammad R., Landsburg, Daniel J., Schuster, Stephen J., Svoboda, Jakub, Li, Yimei, Borovskiy, Yuliya, Olson, Timothy S., Bagg, Adam, Hexner, Elizabeth O., Babushok, Daria V.
Publié dans PLoS One (2019)

Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome

par Lewis, Daniel J., Haun, Paul L., Samimi, Sara S., Vittorio, Carmela C., Villasenor-Park, Jennifer, Barta, Stefan K., Landsburg, Daniel J., Svoboda, Jakub, Nasta, Sunita D., Schuster, Stephen J., Rook, Alain H., Kim, Ellen J.
Publié dans JAMA Dermatol (2020)

Ibrutinib-associated Arthralgias/Myalgias in Patients with Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes

par Rhodes, Joanna M., LoRe, Vincent, Mato, Anthony R., Chong, Elise A., Barrientos, Jacqueline C., Gerson, James N., Barta, Stefan K., Landsburg, Daniel J., Nasta, Sunita Dwivedy, Svoboda, Jakub, Loren, Alison W., Schuster, Stephen J.
Publié dans Clin Lymphoma Myeloma Leuk (2020)

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy

par Landsburg, Daniel J., Hughes, Mitchell E., Koike, Alexa, Bond, David, Maddocks, Kami J., Guo, Ling, Winter, Allison M., Hill, Brian T., Ondrejka, Sarah L., Hsi, Eric D., Nasta, Sunita D., Svoboda, Jakub, Schuster, Stephen J., Bogusz, Agata M.
Publié dans Blood Adv (2019)

Impact of oncogene rearrangement patterns on outcomes in double-hit non-Hodgkin lymphoma patients

par Landsburg, Daniel J., Petrich, Adam M., Abramson, Jeremy S., Sohani, Aliyah R., Press, Oliver, Cassaday, Ryan, Chavez, Julio C., Song, Kevin, Zelenetz, Andrew D., Gandhi, Mitul, Shah, Namrata, Fenske, Timothy S., Jaso, Jesse, Medeiros, L. Jeffrey, Yang, David T., Nabhan, Chadi
Publié dans Cancer (2015)

Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma

par Qian, Lei, Soderquist, Craig, Schrank-Hacker, April, Strauser, Honore, Dupoux, Vanessa, Tang, Chi Ngong, Smith, Jennifer R., Sun, Ang, Majumdar, Sonali, Nguyen, Tran, Widura, Sandy, Landsburg, Daniel J., Schuster, Stephen J., Baxter, Richard H. G., Bogusz, Agata M.
Publié dans Am J Hematol (2019)

Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia

par Frey, Noelle V., Gill, Saar, Hexner, Elizabeth O., Schuster, Stephen, Nasta, Sunita, Loren, Alison, Svoboda, Jakub, Stadtmauer, Edward, Landsburg, Daniel J., Mato, Anthony, Levine, Bruce L., Lacey, Simon F., Melenhorst, Jan Joseph, Veloso, Elizabeth, Gaymon, Avery, Pequignot, Edward, Shan, Xinhe, Hwang, Wei-Ting, June, Carl H., Porter, David L.
Publié dans J Clin Oncol (2020)

Impact of Pre-transplant Therapy and Depth of Disease Response prior to Autologous Transplantation for Multiple Myeloma

par Vij, Ravi, Kumar, Shaji, Zhang, Mei-Jie, Zhong, Xiaobo, Huang, Jiaxing, Dispenzieri, Angela, Abidi, Muneer H., Bird, Jennifer M., Freytes, César O., Gale, Robert Peter, Kindwall-Keller, Tamila L., Kyle, Robert A., Landsburg, Daniel J., Lazarus, Hillard M., Munker, Reinhold, Roy, Vivek, Sharma, Manish, Vogl, Dan T., Wirk, Baldeep, Hari, Parameswaran N.
Publié dans Biol Blood Marrow Transplant (2014)

Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis

par Bair, Steven M., Strelec, Lauren E., Feldman, Tatyana A., Ahmed, Gulrayz, Armand, Philippe, Shah, Nirav N., Singavi, Arun N., Reddy, Nishitha, Khan, Nadia, Andreadis, Charalambos, Vu, Khoan, Huntington, Scott F., Giri, Smith, Ujjani, Chaitra, Howlett, Christina, Faheem, Malik, Youngman, Matthew R., Nasta, Sunita D., Landsburg, Daniel J., Schuster, Stephen J., Svoboda, Jakub
Publié dans Oncologist (2018)

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas

par Svoboda, Jakub, Bair, Steven M., Landsburg, Daniel J., Nasta, Sunita Dwivedy, Nagle, Sarah J., Barta, Stefan K., Khan, Nadia, Filicko-O'Hara, Joanne, Gaballa, Sameh, Strelec, Lauren, Chong, Elise, Mitnick, Sheryl, Waite, Terease S., King, Cara, Ballard, Hatcher, Youngman, Matthew, Gerson, James, Plastaras, John P., Maity, Amit, Bogusz, Agata M., Hung, Stacy S., Nakamura, Hisae, Nejati, Reza, Steidl, Christian, Lim, Megan, Ruella, Marco, Schuster, Stephen J.
Publié dans Haematologica (2020)

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

par Torka, Pallawi, Kothari, Shalin K., Sundaram, Suchitra, Li, Shaoying, Medeiros, L. Jeffrey, Ayers, Emily C., Landsburg, Daniel J., Bond, David A., Maddocks, Kami J., Giri, Anshu, Hess, Brian, Pham, Luu Q., Advani, Ranjana, Liu, Yang, Barta, Stefan Klaus, Vose, Julie M., Churnetski, Michael C., Cohen, Jonathon B., Burkart, Madelyn, Karmali, Reem, Zurko, Joanna, Mehta, Amitkumar, Olszewski, Adam J., Lee, Sarah, Hill, Brian T., Burns, Timothy F., Lansigan, Frederick, Rabinovich, Emma, Peace, David, Groman, Adrienne, Attwood, Kristopher, Hernandez-Ilizaliturri, Francisco J.
Publié dans Blood Adv (2020)